Eli Lilly has spent the last decade transforming from a reliable but unremarkable dividend payer into one of the most talked-about stocks on Wall Street. Its obesity and diabetes franchise, built around tirzepatide, the active Read more…
War headlines have a way of making every portfolio feel fragile. For three straight weeks, the Iran conflict did exactly that. It sent oil prices soaring roughly 40% since the first U.S.-Israeli strikes on February Read more…